Xue Y - Search Results

1

A Pilot Study to Assess the Suitability of Riboflavin as A Surrogate Marker of Breast Cancer Resistance Protein (BCRP) in Healthy Participants.

Shen H, Huo R, Zhang Y, Wang L, Tong N, Chen W, Paris AJ, Mensah K, Chen M, Xue Y, Li W, Sinz M. Shen H, et al. Among authors: xue y. J Pharmacol Exp Ther. 2024 Jan 31:JPET-AR-2023-002015. doi: 10.1124/jpet.123.002015. Online ahead of print. J Pharmacol Exp Ther. 2024. PMID: 38296646 Free article.

2

Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein-Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In Vivo.

Zhang Y, Shipkova PA, Warrack BM, Nelson DM, Wang L, Huo R, Chen J, Panfen E, Chen XQ, Fancher RM, Ruan Q, Christopher LJ, Xue Y, Sinz M, Shen H. Zhang Y, et al. Among authors: xue y. Drug Metab Dispos. 2023 Jul;51(7):851-861. doi: 10.1124/dmd.123.001284. Epub 2023 Apr 13. Drug Metab Dispos. 2023. PMID: 37055191

3

Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions.

Chu J, Panfen E, Wang L, Marino A, Chen XQ, Fancher RM, Landage R, Patil O, Desai SD, Shah D, Xue Y, Sinz M, Shen H. Chu J, et al. Among authors: xue y. Pharm Res. 2023 Nov;40(11):2567-2584. doi: 10.1007/s11095-023-03563-4. Epub 2023 Jul 31. Pharm Res. 2023. PMID: 37523014

4

Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.

Gaudy A, Atsriku C, Ye Y, MacGorman K, Liu L, Xue Y, Surapaneni S, Palmisano M. Gaudy A, et al. Among authors: xue y. Eur J Clin Pharmacol. 2021 Feb;77(2):223-231. doi: 10.1007/s00228-020-03004-w. Epub 2020 Sep 23. Eur J Clin Pharmacol. 2021. PMID: 32965548 Clinical Trial.

5

Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment.

Zhang D, Raghavan N, Wang L, Xue Y, Obermeier M, Chen S, Tao S, Zhang H, Cheng PT, Li W, Ramanathan R, Yang Z, Humphreys WG. Zhang D, et al. Among authors: xue y. Drug Metab Dispos. 2011 Jan;39(1):123-31. doi: 10.1124/dmd.110.035048. Epub 2010 Sep 28. Drug Metab Dispos. 2011. PMID: 20876787

6

Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.

Ogasawara K, Wood-Horrall RN, Thomas M, Thomas M, Liu L, Liu M, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G. Ogasawara K, et al. Among authors: xue y. Cancer Chemother Pharmacol. 2021 Dec;88(6):941-952. doi: 10.1007/s00280-021-04346-7. Epub 2021 Sep 3. Cancer Chemother Pharmacol. 2021. PMID: 34477937

7

Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.

Ogasawara K, Kam J, Thomas M, Liu L, Liu M, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G. Ogasawara K, et al. Among authors: xue y. Cancer Chemother Pharmacol. 2021 Sep;88(3):369-377. doi: 10.1007/s00280-021-04292-4. Epub 2021 May 21. Cancer Chemother Pharmacol. 2021. PMID: 34019108 Clinical Trial.

8

An open-label, phase 1, randomized, three treatments, three-period, crossover, relative bioavailability study of CC-292, a potent and orally available inhibitor of bruton tyrosine kinase.

Cheng Y, Liu L, Xue Y, Zhou S, Li Y. Cheng Y, et al. Among authors: xue y. J Clin Pharm Ther. 2022 Aug;47(8):1186-1193. doi: 10.1111/jcpt.13653. Epub 2022 Mar 20. J Clin Pharm Ther. 2022. PMID: 35307850 Clinical Trial.

9

Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.

Chen Y, Ogasawara K, Wood-Horrall R, Thomas M, Thomas M, He B, Liu L, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G. Chen Y, et al. Among authors: xue y. Cancer Chemother Pharmacol. 2022 Oct;90(4):325-334. doi: 10.1007/s00280-022-04464-w. Epub 2022 Aug 24. Cancer Chemother Pharmacol. 2022. PMID: 36001108 Free PMC article.

10

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects.

Cheng Y, Ye Y, Gaudy A, Ghosh A, Xue Y, Wang A, Zhou S, Li Y. Cheng Y, et al. Among authors: xue y. Clin Pharmacol. 2023 Feb 28;15:9-19. doi: 10.2147/CPAA.S397826. eCollection 2023. Clin Pharmacol. 2023. PMID: 36880014 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10,463 results

Search Page